BCYC:NSD-Bicycle Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.29

Change

+0.29 (+1.45)%

Market Cap

USD 0.39B

Volume

0.05M

Average Target Price

USD 26.00 (+28.14%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.76 (-1.41%)

USD69.70B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

-6.32 (-1.11%)

USD60.80B 21.90 16.92
SGEN Seattle Genetics, Inc

-2.68 (-1.47%)

USD31.66B N/A N/A
MRNA Moderna, Inc

-1.56 (-2.27%)

USD27.12B N/A N/A
RPRX Royalty Pharma plc

+0.06 (+0.14%)

USD25.33B 35.72 9.73
GMAB Genmab A/S

-2.15 (-5.63%)

USD25.18B 27.12 3.06
ALXN Alexion Pharmaceuticals, Inc

-2.08 (-1.82%)

USD25.10B 30.43 27.52
BGNE BeiGene, Ltd

+5.88 (+2.19%)

USD24.63B N/A N/A
IMMU Immunomedics, Inc

+0.12 (+0.14%)

USD19.66B N/A N/A
INCY Incyte Corporation

-0.96 (-1.10%)

USD19.01B 47.64 35.20

ETFs Containing BCYC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 115.16% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.16% 90% A- 93% A
Trailing 12 Months  
Capital Gain 82.46% 79% C+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.46% 79% C+ 89% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 22.39% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.39% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.11% N/A N/A N/A N/A
Risk Adjusted Return 50.76% N/A N/A N/A N/A
Market Capitalization 0.39B 56% F 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2,065.00 1% F 1% F
Price/Book Ratio 5.61 39% F 24% F
Price / Cash Flow Ratio -13.48 74% C 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.52% 71% C- 26% F
Return on Invested Capital -222.87% 8% F 3% F
Return on Assets -20.03% 69% D+ 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.08 40% F 27% F
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.